In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From PAION AG

Digital Health Roundup: VR, AI Trends In Rehabilitation; Cybersecurity Regulations; Medicare Updates

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights VR, AI and other high tech trends in rehabilitation and gait training. Hannah Daniel discusses cybersecurity updates such as the new NIST published draft for an updated version of the Cybersecurity Framework, a recent report by Health-ISAC, and an interview with MedCrypt’s Naomi Schwartz about the upcoming FDA cybersecurity regulations for premarket approvals.

Digital Health Artificial Intelligence

ReWalk Robotics’ Planned Acquisition Of Anti-Gravity Maker AlterG For $19M Paves Way To Profitability

ReWalk Robotics’ planned $19m acquisition of AlterG will put ReWalk on the path to profitability and positive cash flow, creating a combined company with trailing 12-month revenues of about $26m.

M & A Deals

Finance Watch: Turnstone Biologics Launches 14th Biopharma IPO Of 2023

Turnstone’s initial public offering comes just one week after Apogee and Sagimet launched US IPOs. Also, Westlake Village BioPartners raised $450m for its third venture capital fund and argenx grossed $1.27bn in a post-Phase III follow-on offering.

Financing Growth

In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill

Alnylam is using its RNA interference technology to target hypertension, which could create a true mass-market cardiovascular blockbuster drug for the firm – but upcoming Phase II data will need to be compelling.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • CeNeS Pharmaceuticals plc.
UsernamePublicRestriction

Register